Sr Director, US Medical Early Assets - Market Access

AstraZeneca • Wilmington, DE

8d • Hybrid

About The Position

The Sr Director, US Medical Early Assets - Market Access is responsible for developing ambitious US medical strategies for AstraZeneca's early pipeline. This role involves influencing across a complex global matrix to ensure US payer, health-system, policy, and affordability needs are integrated into asset development and investment decisions. The Senior Director will shape the US access and value strategy for BBU portfolio pipeline assets from late discovery through Phase 2, ensuring payer, health-system, policy, pricing, and affordability considerations are incorporated early into asset development, evidence generation, and investment decisions. Serving as the senior US access voice on cross-functional asset teams, the Senior Director provides clear, evidence-based recommendations to strengthen future differentiation, reimbursement, and patient access.

Requirements

• Bachelor's degree in health economics, public health, pharmacy, life sciences, business, economics, or a related discipline.
• 8+ years of progressive experience in the pharmaceutical, biotechnology, healthcare, payer, or consulting environment, including substantial experience in US Market Access, HEOR, pricing and reimbursement, or early asset strategy.
• Profiles, clinical development plans, evidence strategies, and asset investment decisions.
• Deep understanding of the US payer and healthsystem environment, including commercial and government payers, medical and pharmacy benefit dynamics, pricing and reimbursement, utilization management, distribution and site-of-care considerations, and relevant policy trends.
• Strong understanding of HEOR, realworld evidence, payer research, economic modeling, and value proposition development, with the ability to translate technical analyses into strategic recommendations.
• Demonstrated experience representing a function or market perspective on cross-functional asset teams, governance forums, or senior decision-making bodies.
• Proven ability to influence senior stakeholders and lead across Clinical Development, Medical, HEOR, Regulatory, Commercial, Finance, Policy, and global market access organizations without direct authority.
• Strong strategic judgment and the ability to make clear recommendations in conditions of scientific, commercial, and access uncertainty.
• Excellent communication skills, including the ability to synthesize complex information, construct a compelling value narrative, and influence senior and global stakeholders.
• Demonstrated ability to manage multiple assets, priorities, and decision timelines in a complex, matrixed environment.

Nice To Haves

• Advanced degree such as an MPH, MS, PharmD, PhD, or MBA strongly preferred.
• Advanced degree in health economics, outcomes research, public health, pharmacy, medicine, science, economics, or business.
• Experience spanning more than one relevant discipline, such as Market Access, HEOR, Clinical Development, Medical Affairs, new product planning, pricing, policy, or finance.
• Direct experience supporting early-stage or first-in-class assets from late discovery through Phase 2.
• Experience influencing global asset strategy and translating US access needs into global development and evidence plans.
• Experience contributing to governance decisions involving asset progression, indication prioritization, evidence investment, licensing, or portfolio prioritization.
• Experience developing innovative pricing, contracting, or value-based access approaches.
• Therapeutic-area experience relevant to the assigned pipeline portfolio.
• Experience coaching colleagues or building organizational capability in early market access, HEOR, payer strategy, or value development.

Responsibilities

• Define US payer-relevant elements of the Target Product Profile (clinical endpoints, comparators, subpopulations, line of therapy) and shape differentiation claims that resonate with payers and health systems.
• Provide US access input to clinical and RWE plans (endpoints, PROs, inclusion/exclusion, head-to-heads, external controls) to support label, compendia, guideline inclusion, and payer coverage.
• Lead early value story development (unmet need, clinical and economic value drivers), outline core claims, and define requirements for future AMCP dossier modules and global value dossiers.
• Develop US WAC/NET ranges, reference pricing considerations, budget impact boundaries, and contracting scenarios (e.g., outcomes-based, indication-based) with assumptions and risks.
• Co-create early economic models and RWE plans (burden of illness, treatment patterns, comparative effectiveness, adherence/persistence) to support access and inform trial design.
• Assess policy landscape (Medicare, Medicaid, ACA, IRA/Part D redesign, 340B, state policies), site-of-care and channel dynamics (buy-and-bill, pharmacy benefit, specialty distribution), and implications for design and launch.
• Plan and synthesize early payer/IDN advisory input and rapid tests (concept reviews, value message testing, coverage criteria simulations) to de-risk access hurdles.
• Maintain landscape of class coverage criteria, step/edit rules, utilization management, coding/reimbursement precedents; identify opportunities to differentiate and anticipate barriers.
• Build access assumptions for early forecasts (gross-to-net, access mix, UM intensity, speed-to-coverage) and partner with Finance on rNPV/scenario analyses for governance.
• Represent US access in global/US asset teams and at governance gates (indication sequencing, go/no-go, TPP approval), driving clear, evidence-backed recommendations.
• Operate within US promotional and pre-approval communication standards and company policies; ensure research and external interactions meet compliance requirements.

Benefits

• When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working gives us the platform we need to connect, work at pace and challenge perceptions. That's why we work, on average, a minimum of three days per week from the office. But that doesn't mean we're not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.

What This Job Offers

• Job Type: Full-time
• Career Level: Senior